Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines

M. Šmahel, I. Poláková, E. Sobotková, E. Vajdová

. 2011 ; 2011 () : 176759. [pub] 20111018

Jazyk angličtina Země Egypt

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022182

DNA vaccines showed great promise in preclinical models of infectious and malignant diseases, but their potency was insufficient in clinical trials and is needed to be improved. In this study, we tested systemic administration of two conventional adjuvants, synthetic oligodeoxynucleotide carrying immunostimulatory CpG motifs (CpG-ODN) and levamisole (LMS), and evaluated their effect on immune reactions induced by DNA vaccines delivered by a gene gun. DNA vaccination was directed either against the E7 oncoprotein of human papillomavirus type 16 or against the BCR-ABL1 oncoprotein characteristic for chronic myeloid leukemia. High doses of both adjuvants reduced activation of mouse splenic CD8(+) T lymphocytes, but the overall antitumor effect was enhanced in both tumor models. High-dose CpG-ODN exhibited a superior adjuvant effect in comparison with any combination of CpG-ODN with LMS. In summary, our results demonstrate the benefit of combined therapy with gene-gun-delivered antitumor DNA vaccines and systemic administration of CpG-ODN or LMS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022182
003      
CZ-PrNML
005      
20160215091414.0
007      
ta
008      
120806s2011 ua f 000 0#eng||
009      
AR
024    7_
$a 10.1155/2011/176759 $2 doi
035    __
$a (PubMed)22028727
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ua
100    1_
$a Šmahel, Michal $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic $7 xx0060364
245    10
$a Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines / $c M. Šmahel, I. Poláková, E. Sobotková, E. Vajdová
520    9_
$a DNA vaccines showed great promise in preclinical models of infectious and malignant diseases, but their potency was insufficient in clinical trials and is needed to be improved. In this study, we tested systemic administration of two conventional adjuvants, synthetic oligodeoxynucleotide carrying immunostimulatory CpG motifs (CpG-ODN) and levamisole (LMS), and evaluated their effect on immune reactions induced by DNA vaccines delivered by a gene gun. DNA vaccination was directed either against the E7 oncoprotein of human papillomavirus type 16 or against the BCR-ABL1 oncoprotein characteristic for chronic myeloid leukemia. High doses of both adjuvants reduced activation of mouse splenic CD8(+) T lymphocytes, but the overall antitumor effect was enhanced in both tumor models. High-dose CpG-ODN exhibited a superior adjuvant effect in comparison with any combination of CpG-ODN with LMS. In summary, our results demonstrate the benefit of combined therapy with gene-gun-delivered antitumor DNA vaccines and systemic administration of CpG-ODN or LMS.
650    _2
$a adjuvancia imunologická $x aplikace a dávkování $7 D000276
650    _2
$a zvířata $7 D000818
650    _2
$a biolistika $7 D019470
650    _2
$a CD8-pozitivní T-lymfocyty $x účinky léků $x metabolismus $x patologie $7 D018414
650    _2
$a protinádorové vakcíny $7 D019496
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a bcr-abl fúzní proteiny $x genetika $x imunologie $x metabolismus $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a imunita $x účinky léků $7 D007109
650    _2
$a levamisol $x aplikace a dávkování $7 D007978
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a experimentální nádory $x imunologie $x patologie $x terapie $7 D009374
650    _2
$a oligodeoxyribonukleotidy $x aplikace a dávkování $7 D009838
650    _2
$a Papillomavirus E7 - proteiny $x genetika $x imunologie $x metabolismus $7 D050725
650    _2
$a DNA vakcíny $7 D019444
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Poláková, Ingrid $7 xx0139787 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Sobotková, Eva $7 xx0103776 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Vajdová, Eva $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
773    0_
$w MED00013777 $t Clinical & developmental immunology $x 1740-2530 $g Roč. 2011(2011), s. 176759
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22028727 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20160215091557 $b ABA008
999    __
$a ok $b bmc $g 944095 $s 779479
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 2011 $d 176759 $e 20111018 $i 1740-2530 $m Clinical & developmental immunology $n Clin Dev Immunol $x MED00013777
LZP    __
$b NLK111 $a Pubmed-20120806/12/01
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace